rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

CeriBell, Inc.

CBLL · Nasdaq

Health CareMedical DevicesIn trendAI

CBLL stood above a rising 150-day average in 31 of the last 52 weekly readings, including each of the last 7 weeks. It is 21.8% above that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
7 in a row
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$41.1M
Officials’ trades on record
0
Institutions holding
122 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 31 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$9.5M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months68
Buyers · sellers0 · 11
WhoDidSharesTraded
Raymond WooChief Technology Officersold4,887at $24.381 Oct 2026filed 2 Oct 2026
Scott BlumbergChief Financial Officersold846at $25.0015 Sep 2026filed 17 Sep 2026
Xingjuan ChaoPresident and CEOsold20,846at $25.0315 Sep 2026filed 17 Sep 2026
Raymond WooChief Technology Officersold4,887at $24.338 Sep 2026filed 10 Sep 2026
David FoehrSenior VP, Finance and PAOsold1,755at $24.268 Sep 2026filed 10 Sep 2026
David FoehrSenior VP, Finance and PAOsold7,500at $24.258 Sep 2026filed 10 Sep 2026
Scott BlumbergChief Financial Officersold652at $25.002 Sep 2026filed 4 Sep 2026
Xingjuan ChaoPresident and CEOsold39,540at $24.612 Sep 2026filed 4 Sep 2026
David FoehrSenior VP, Finance and PAOsold859at $23.9524 Aug 2026filed 25 Aug 2026
Xingjuan ChaoPresident and CEOsold6,068at $24.0221 Aug 2026filed 25 Aug 2026
Scott BlumbergChief Financial Officersold1,521at $24.0221 Aug 2026filed 25 Aug 2026
Raymond WooChief Technology Officersold1,979at $24.0221 Aug 2026filed 25 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders122+4 on the quarter
New · exited19 · 14
Reported value$594.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FMR LLCadded · filed 13 Aug 20265,691,393$110.7M+840,962+17.3%
TPG GP A, LLCreduced · filed 14 Aug 20263,761,154$73.2M-206,268−5.2%
RED TREE MANAGEMENT, LLCunchanged · filed 22 Jul 20262,205,661$42.9M00.0%
BlackRock, Inc.added · filed 7 Aug 20261,936,093$37.7M+122,938+6.8%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20261,130,346$22.0M-6,786−0.6%
KCM Capital Increduced · filed 12 Aug 20261,125,000$21.9M-275,000−19.6%
FEDERATED HERMES, INC.added · filed 12 Aug 2026939,600$18.3M+1360.0%
FRANKLIN RESOURCES INCadded · filed 13 Aug 2026918,349$17.9M+108,835+13.4%
ADAGE CAPITAL PARTNERS GP, L.L.C.added · filed 14 Aug 2026900,000$17.5M+143,249+18.9%
Bank of New York Mellon Corpreduced · filed 6 Aug 2026896,488$17.4M-264,279−22.8%
31 Dec 2024 – 30 Jun 2026
7698120Dec 24Jun 25Sep 25Mar 26Jun 26

Everyone who traded it

Raymond Woo Company insiderChief Technology Officer · last 1 Oct 20260 · 14
Scott Blumberg Company insiderChief Financial Officer · last 15 Sep 20260 · 8
Xingjuan Chao Company insiderPresident and CEO · last 15 Sep 20260 · 25
David Foehr Company insiderSenior VP, Finance and PAO · last 8 Sep 20260 · 12
Joseph S. Manni Company insiderChief Revenue Officer · last 21 Aug 20260 · 3
Joseph Michael Taylor Company insiderDirector · last 13 Aug 20260 · 3
Sharon O'Keefe Company insiderDirector · last 28 Jul 20260 · 0
Thomas A. West Company insiderDirector · last 28 Jul 20260 · 0
William W. Burke Company insiderDirector · last 30 Jun 20260 · 2
James G. Coulter Company insiderOther · last 26 Jun 20260 · 1
TPG GP A, LLC Company insiderOther · last 26 Jun 20260 · 1
Bakker Juliet Tammenoms Company insiderDirector · last 2 Jun 20261 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202587.9%
Operating profit marginFY 2025 · to 31 Dec 2025-65.6%
Free cash flow marginFY 2025 · to 31 Dec 2025-46.7%
Return on capital employedFY 2025 · to 31 Dec 2025-33.1%
Research spendFY 2025 · to 31 Dec 202521.5%
Share count trendFY 2025 · to 20 Feb 20260.4%
Cash and equivalentsFY 2025 · to 31 Dec 2025$40.5M
Free cash flowFY 2025 · to 31 Dec 2025−$41.6M

Analyst forecasts

No analyst forecasts yet.